Adjuvant tyrosine kinase inhibitors plus anti-PD-1 therapy reduce recurrence in high-risk hepatocellular carcinoma after resection

Background/aimsNo standardized adjuvant treatment has been established for patients with hepatocellular carcinoma (HCC) following curative resection. This study aimed to evaluate the efficacy and safety of adjuvant tyrosine kinase inhibitors (TKIs) in combination with anti-programmed death-1 (PD-1)...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Jiaxin Li, Yukun Sun, Ziniu Liu, Jianwen Huang, Jian Wu, Yun Huang, Yali Gao, Baomin Chen, Qiang He
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2025-11-01
Ráidu:	Frontiers in Oncology
Fáttát:	hepatocellular carcinoma high risk of recurrence tyrosine kinase inhibitors (TKIs) anti-PD-1 antibodies postoperative adjuvant therapy
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1710602/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!